Zenith Capital (Zenith Capital) Debt-to-Asset : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Debt-to-Asset?

Zenith Capital's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Zenith Capital's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in . 20 was $0.00 Mil.

Zenith Capital Debt-to-Asset Historical Data

The historical data trend for Zenith Capital's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Debt-to-Asset Chart

Zenith Capital Annual Data

Trend

Debt-to-Asset

Zenith Capital Quarterly Data

Debt-to-Asset

Competitive Comparison of Zenith Capital's Debt-to-Asset

For the Biotechnology subindustry, Zenith Capital's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Debt-to-Asset falls into.

Zenith Capital Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Zenith Capital's Debt-to-Asset for the fiscal year that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Zenith Capital's Debt-to-Asset for the quarter that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Zenith Capital (OTCPK:ZHCLF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Zenith Capital Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines